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Abstract
Background: Malignant lymphomas constitute a diverse group of cancers of lymphocytes. One well-known disease
is Hodgkin’s lymphoma; the others are classified as non-Hodgkin’s lymphoma (NHL). NHLs are the most common
hematologic neoplasms in adults worldwide, and in 2012 over 170,000 new cases were estimated in the United
States and Europe.
In previous studies, several practice gaps in hospital care for patients with NHL have been identified. To decrease
this variation in care, the present study aims to perform a problem analysis in which barriers to and facilitators for
optimal NHL care will be identified and, based on these findings, to develop (tailored) improvement strategies.
Subsequently, we will assess the effectiveness, feasibility and costs of the improvement strategies.
Methods/design: Barriers and facilitators will be explored using the literature, using interviews and questionnaires
among physicians involved in NHL care, and patients diagnosed with NHL. The results will be used to develop a
tailored improvement strategy. A cluster randomized controlled trial involving 19 Dutch hospitals will be
conducted. Hospitals will be randomized to receive either an improvement strategy tailored to the barriers and
facilitators found or, a standard strategy of audit and feedback.
The effects of both strategies will be evaluated using previously developed quality indicators. Adherence to the
indicators will be measured before and after the intervention period based on medical records from newly
diagnosed NHL patients. To study the feasibility of both strategies, a process evaluation will be additionally
performed. Data about exposure to the different elements of the strategies will be collected using questionnaires.
Economic evaluation from a healthcare perspective will compare the two implementation strategies, where the
costs of the implementation strategy and changes in healthcare consumption will be assessed.
Discussion: The presence of variation in the use of diagnostic tests, treatment, and follow-up between different
physicians in different hospitals in the Netherlands is important for patients. To reduce the existing variation in care,
implementation of tailored interventions to improve NHL care is necessary.
Trial registration: This trial is registered at ClinicalTrial.gov as the PEARL study, registration number NCT01562509.
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Background
Malignant lymphomas represent a heterogeneous group
of malignant lymphocyte proliferations, which can be
classified as either Hodgkin’s lymphoma (HL) or non-
Hodgkin’s lymphoma (NHL). NHLs are the sixth most
common malignant neoplasm in the United States [1]
and the most common hematologic neoplasm in adults
worldwide [2]. In 2012, the estimated number of new
cases was 79,000 for the United States [1] and over 93,000
for Europe [3]. NHL constitute of more than 40 disease
entities. The most prevalent are diffuse large B-cell lymph-
oma, follicular lymphoma, marginal zone cell lymphoma,
small lymphocytic lymphoma and mantle cell lymphoma,
together accounting for 80% of all NHL [4].
Evidence-based guidelines on diagnosis, treatment, and
follow-up of patients with NHL have been developed dur-
ing the past years and provide recommendations for high
quality NHL care [5-11]. These national and international
guidelines support physicians as well as patients in their
decisions about diagnosis, therapy, and follow-up. In gen-
eral, publication and distribution of these guidelines is not
sufficient to maximize their effect on the quality of care
[12], hence active implementation is needed. Several stud-
ies demonstrated suboptimal care for patients with NHL
[13-15]. They described large gaps between daily practice
and high-quality NHL care as recommended in the guide-
line. This lack of guideline adherence concerned, among
others, diagnostics, therapy, and prognostic parameters.
For example, in 22 Dutch hospitals, adherence was lowest
for assessment of International Prognostic Index (IPI),
documentation of indicator lesions found on CT-scans
during diagnostics and after therapy, adequate pathology
reporting, and discussing patients during multidisciplin-
ary consultations [15]. The clinical relevance of guide-
line adherence is shown in several cancer studies
[16-20]. These studies showed that better adherence to
guidelines is associated with better overall survival or
progression-free survival.
To improve quality of NHL care, it is important to know
what the barriers to and facilitators for high-quality NHL
care are. Based on this, tailored interventions can be
developed to improve the quality of care. Most theories on
implementation of evidence in healthcare emphasize as-
sessment of influencing factors first, in order to acquire a
tailor-made improvement strategy [21,22]. Several models
have shown to be effective in structuring the experienced
barriers and facilitators [23-25]. In the final steps, the
strategies can be tested and evaluated.
Aim and objectives
This study aims to perform a problem analysis in which
barriers and facilitators for optimal NHL care will be
identified. Based on these findings, we intend to develop
(tailored) improvement strategies, and assess their effect-
iveness, feasibility and costs.
Main objectives that will be investigated are:
1. To explore barriers and facilitators according to
patients and physicians, that influence optimal NHL
care as described in evidence based NHL guidelines,
2. To gain insight into the current NHL care based on
previously developed quality indicators.
3. To develop, test, and evaluate the improvement
strategies, tailored to the barriers found and current
practice.
Methods
The objectives of this study will be examined in a cluster
randomized controlled trial (cRCT), preceded by a
problem analysis.
Problem analysis
Design and methods
Barriers and facilitators for delivering optimal care will
be investigated at different levels. For the classification
of the influencing factors a framework developed by
Cabana [23] and Grol [25] will be used. This framework
includes features of the guidelines; features of the target
group of physicians; features of patients; features of the
social context (e.g., colleagues of the involved physicians
and geographic distance to hospital); and features of the
organizational context.
To detect possible barriers and facilitators regarding
optimal NHL care, a literature study will be performed.
Second, a qualitative study will be conducted on the
basis of (small group) interviews among physicians in-
volved in NHL care and on individual interviews with
NHL patients. The interviewer will follow the framework
as described above during the semi-structured interviews
to explore influencing factors. This method will provide
us with barriers and facilitators at different levels (e.g.,
patient, physician, as well as the organization). Finally, a
questionnaire survey will be performed to quantify the
features mentioned in the (small group) interviews. All
participants will receive a web-based questionnaire by
email and asked to fill in this questionnaire. The data
will be gathered in an electronic database.
Study population and setting
Four small group interviews with seven to 10 physicians
will be conducted. Physicians, including hematologists,
pathologists, radiation oncologists, radiologists, and nu-
clear medicine physicians, from 22 hospitals involved in
a previous NHL study [15] will be invited to participate
in the interviews. These hospitals include university,
teaching, and non-teaching hospitals. Patients will be
invited to take part in the individual interviews by the
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Dutch Lymphoma Organization (LVN) and their attend-
ing physician. The interviews will be held with 15 to 20
patients until saturation has been reached. The question-
naire survey will be performed among 200 physicians
and patients. To select the participants, we will contact
the national professional associations of all professions
involved and request e-mail addresses. Additionally, the
LVN will be asked to invite patients via their website.
Outcome measures
Barriers and facilitators regarding optimal NHL care based
on evidence-based multidisciplinary NHL guidelines. They
will be classified within the framework developed by
Cabana and Grol [23,25].
Data analysis
The barriers and facilitators mentioned in the interviews
with physicians and patients will be qualitatively ana-
lyzed using the software Atlas.ti® (version 6.2.23, Atlas.ti
Scientific Software Development GmbH; Berlin, Germany)
and will be descriptive. Potential barriers and facilitators
will be identified independently by two members of the
project team, and any discrepancies will be discussed until
consensus is reached.
The influencing factors from these interviews are quan-
tified on the basis of questionnaire surveys conducted
among physicians and patients to assess the most
frequently mentioned barriers and facilitators. Analysis of
the questionnaires will be descriptive (i.e., frequencies and
means).
Cluster randomized controlled trial
Design and methods
Based on the results of the problem analysis and the care
measurements of Wennekes et al. [15], tailored interven-
tions will be developed in order to increase indicator
adherence. Current care will be assessed before start of
the intervention period and the tailored interventions
will be adjusted if necessary.
The interventions will be tested in a cRCT in 19 Dutch
hospitals. The hospitals will be the level of randomization
which includes two arms: centers receiving a standard
strategy of audit and feedback, and centers receiving the
standard strategy followed by an improvement strategy
tailored to the barriers and facilitators found. Both
strategies will be evaluated with an effect-, process-, and
cost-evaluation. In the effect evaluation, the previously
developed quality indicators will be used as effect mea-
sures: before and after implementing the strategies,
quality indicator adherence will be assessed by retro-
spective searches in medical records by the Comprehen-
sive Cancer Centre the Netherlands (CCC). After the
intervention period, patients as well as physicians will
be asked to fill out a questionnaire concerning the use
and experiences with the interventions tested. Semi-
structured interviews in each hospital will give insight
into the processes concerning implementation of the
interventions and local initiatives to improve NHL care
during the intervention period. Costs of the interven-
tions and the accompanied changes in consumption of
care will be assessed as well.
Study population and setting
Nineteen hospitals, including university, teaching, and
non-teaching hospitals, and their physicians involved in
NHL care will participate in this study. Hospitals that
participated in a previous NHL study [15] will be invited
to take part in the current cRCT. An invitation letter will
be send by email to the contact persons, accompanied by
an informed consent.
Randomization will take place after formal agreement of
all hospitals to participate in the trial and will be based on
randomly generated numbers (computer based) stratified
by hospital size (small, medium, and large). The contact
persons of all participating hospitals will be informed of
the allocation after collection of the baseline measure-
ment. In all participating hospitals, the trial will be
conducted between November 2012 and June 2014.
Per hospital, approximately 22 newly diagnosed NHL
patients will be selected for data collection regarding
adherence to the quality indicators. Selection of patients
will take place using the cancer registry, with support of
the CCC. The CCC will use the cancer registry to make
a list of potentially eligible patients in the participating
hospitals. From each list, the first 25 to 30 patients will
be selected, and listed according to day of birth. This
cancer registry is based on the pathology coding system
of the World Health Organization (WHO) and patients
with mature B-, T- and NK-cell neoplasms will be se-
lected for inclusion. Patients diagnosed with cutaneous
or leukemia-type neoplasms will be excluded, as well as
patients younger than 18 years old.
During the intervention period, physicians of the inter-
vention hospitals will hand out patient information
and an informed consent to all newly diagnosed NHL
patients. Physicians are asked to use the different devel-
oped elements to improve quality of care. Patients will
return their informed consent with permission (or
prohibition) for sending them a questionnaire at the end
of the intervention period. Patients as well as physicians
will be stimulated to actively apply the interventions of
our improvement strategy (when applicable).
Outcome measures
Effect measures
The effect evaluation aims to determine the effectiveness
of the standard audit and feedback strategy versus the
tailored improvement strategy using the previously
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developed quality indicators. Percentage of adherence to
these indicators will be used as a primary measure for
quality of NHL care. The effect measurement will be
done by two assessments, one before and one after
implementation of the improvement strategies. The data
for these indicators will be collected on patient level
from medical records. Additionally, morbidity in the
patient groups, patient-related outcome measures, and
potential confounders of the effects will be evaluated.
Process measures
To study the feasibility of both strategies, the process
evaluation has to give insight into the mechanisms and
processes responsible for the result (i.e., extent of adher-
ence to the indicator set for optimal NHL care). The
actual exposure of the patients and physicians to the
interventions, together with their experience with these
elements may have influenced the final result (success or
failure of indicator adherence).
Data about exposure to the different interventions will
be collected using a combination of data collection
methods (e.g., user data of developed tools and question-
naires for physicians and patients). This information will
be related to effectiveness of the strategy to assess which
interventions were particularly associated with successful
implementation. At the end of the intervention period,
experiences of patients and physicians with the imple-
mentation elements will be measured with question-
naires and/or interviews. This information will be used
to, if necessary, adapt the interventions to make them
more acceptable and effective for implementation on a
national level.
Cost measures
The economic evaluation will compare the two strategies in
a healthcare perspective. Both the costs of the implementa-
tion strategy and changes in healthcare consumption will
be assessed. Although the underlying technologies might
be evaluated well on a national level, the aim of this ana-
lysis is to detect which strategy is the most cost-effective
strategy on optimal care in common practice.
The input of resources in the improvement strategies
will be assessed by collecting volumes of consumed
resources and multiplying these by the price of each
resource unit (market prices, guideline prices, or self-
determined prices based on costing methods, i.e., full
costing) [26,27]. The decision criterion on which the
efficient implementation strategy will be selected is the
incremental cost per gained percentage adherence.
Sample size considerations
We hope to detect a difference in adherence to the indica-
tors between the two strategies of at least 20%. In a previ-
ous study, the mean adherence rate was 40%. To detect a
difference of 20% (40% versus 60%), with alpha = 0.05, a
two-sided testing and power = 0.80, at least 194 NHL
patients are required.
However, considering an intra-cluster correlation coef-
ficient of 0.09 (mean ICC in previous study [15]) and a
hospital cluster correlation of 0.8, in 19 hospitals,
22 patients per hospital are needed (n = 418 patients).
Data analysis
Effect evaluation
Multilevel regression analyses will be performed to
evaluate the effectiveness of both improvement strat-
egies. Patient characteristics as gender, age, tumor type,
and co-morbidity will be collected and included in the
analysis as possible confounders for differences in actual
care between the different hospitals and for differences
in effectiveness between the two strategies.
Process evaluation
Exposure to and experiences with the improvement
strategy elements will be analyzed descriptively. Possible
local initiatives to improve NHL care during the inter-
vention period will also be considered descriptively.
Cost evaluation
The implementation process and consequently (full)
costs of both strategies will be estimated by an Activity
Based Costing (ABC) approach focusing on activities
performed with costs accumulated at the activity level(s)
of the healthcare implementation processes. The incre-
mental costs will be determined by the difference in
resource consumption between the two strategies. Next,
the underlying activities (personnel, material, and over-
head costs) associated with these sub-processes are iden-
tified. Use of ABC concepts facilitates the identification
of non-value-added activities.
The output or consequences of the implementation
strategies will be determined by the level of adherence
to the quality indicators, measured before and after the
intervention period. Adherence will be determined by
using the repeated measures method over the two differ-
ent time intervals. The decision criterion on which
the efficient implementation strategy will be selected is
the incremental cost per gained percentage adherence.
The impact of variable(s) uncertainty on the decision
criterion will be evaluated by sensitivity analyses.
Ethical considerations
In the Netherlands, studies involving human subjects
need to undergo a medical ethics review if they are sub-
ject to the Medical Research Involving Human Subjects
Act (WMO). The Medical Ethics Committee (CMO) of
district Arnhem/Nijmegen assessed the study protocol
and declared that no further ethical approval was required
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(registration number 2011/560). Therefore, using the
described study protocol, the study will be carried out in
accordance with the applicable rules concerning the re-
view of research ethics committees and informed consent.
Trial status
No data cleaning or analysis of the cRCT has been
executed prior to submission of this manuscript.
Discussion
This paper describes the protocol of an improvement
study, consisting of a problem analysis and a cRCT,
to assess barriers and facilitators for optimal NHL care
to develop, test, and evaluate (tailored) improvement
strategies, based on these findings.
The strength of this study is the use of multifaceted
tailored interventions, which may be more effective than
single ones [22,28,29]. Therefore, a strategy with differ-
ent interventions is supposed to be effective, directed at
professional, patient, and organizational level. This strat-
egy accompanies the disadvantage of measuring the effect
of the entire package of interventions, which makes it un-
able to distinguish which intervention was most effective
regarding improved NHL care (with indicator adherence
as effect measure). During the process evaluation, we will
try to get insight into the effectiveness of each separate
intervention by acquiring information from participants
concerning the exposure to, use of, and experiences with
the different interventions.
Local initiatives to optimize NHL care during the
intervention period might bias our study results. There-
fore, information on local, non-study-related interven-
tions will be additionally inquired during the process
evaluation.
The results of this study will contribute to a better
knowledge of barriers and facilitators of optimal NHL
care and thus improvement opportunities. Next to this,
insight will be obtained in the effects of different
strategies on the quality of NHL care, which enables us
to define a preferred improvement strategy. We believe
that the interventions tailored to the barriers found
will optimize NHL care and might be applicable on a
national level in the future.
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